- Home
- MYTE vs DSGN Comparison
MYTE vs DSGN Comparison
Compare MYTE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYTE
- DSGN
- Stock Information
- Founded
- MYTE 2006
- DSGN 2017
- Country
- MYTE Germany
- DSGN United States
- Employees
- MYTE N/A
- DSGN N/A
- Industry
- MYTE Catalog/Specialty Distribution
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MYTE Consumer Discretionary
- DSGN Health Care
- Exchange
- MYTE Nasdaq
- DSGN Nasdaq
- Market Cap
- MYTE 327.4M
- DSGN 264.4M
- IPO Year
- MYTE 2021
- DSGN 2021
- Fundamental
- Price
- MYTE $6.18
- DSGN $5.80
- Analyst Decision
- MYTE Buy
- DSGN Hold
- Analyst Count
- MYTE 2
- DSGN 3
- Target Price
- MYTE $4.88
- DSGN $7.00
- AVG Volume (30 Days)
- MYTE 139.5K
- DSGN 140.3K
- Earning Date
- MYTE 11-19-2024
- DSGN 11-07-2024
- Dividend Yield
- MYTE N/A
- DSGN N/A
- EPS Growth
- MYTE N/A
- DSGN N/A
- EPS
- MYTE N/A
- DSGN N/A
- Revenue
- MYTE $900,945,034.00
- DSGN N/A
- Revenue This Year
- MYTE $11.82
- DSGN N/A
- Revenue Next Year
- MYTE $11.78
- DSGN N/A
- P/E Ratio
- MYTE N/A
- DSGN N/A
- Revenue Growth
- MYTE 9.77
- DSGN N/A
- 52 Week Low
- MYTE $2.23
- DSGN $2.13
- 52 Week High
- MYTE $8.24
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MYTE 48.25
- DSGN 50.20
- Support Level
- MYTE $6.01
- DSGN $5.32
- Resistance Level
- MYTE $6.35
- DSGN $7.77
- Average True Range (ATR)
- MYTE 0.35
- DSGN 0.58
- MACD
- MYTE -0.12
- DSGN 0.05
- Stochastic Oscillator
- MYTE 12.86
- DSGN 27.57
About MYTE MYT Netherlands Parent B.V. each representing one
MYT Netherlands Parent BV is a luxury e-commerce platform. The company offers luxury fashion wear for men, women, and kids. Also, the company sells shoes, bags, and accessories. The company operates in two segments which include the online segment and Retail store segments in which the majority of its revenue is generated from the Online segment.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.